ECSP066327A - Composición de fexofenadina y proceso para prepararla - Google Patents

Composición de fexofenadina y proceso para prepararla

Info

Publication number
ECSP066327A
ECSP066327A EC2006006327A ECSP066327A ECSP066327A EC SP066327 A ECSP066327 A EC SP066327A EC 2006006327 A EC2006006327 A EC 2006006327A EC SP066327 A ECSP066327 A EC SP066327A EC SP066327 A ECSP066327 A EC SP066327A
Authority
EC
Ecuador
Prior art keywords
fexofenadine
prepare
composition
plasma
cmax
Prior art date
Application number
EC2006006327A
Other languages
English (en)
Inventor
Indranil Nandi
Ashish Anilbhai Patel
Moceen Sadatrezaei
Pablo Davila
Virendra Maheshappa Khanapure
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of ECSP066327A publication Critical patent/ECSP066327A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulga una composición farmacéutica que comprende fexofenadina o una sal farmacéuticamente aceptable de la misma, lactosa, una hidroxipropilcelulosa poco sustituida y opcionalmente otros excipientes. Las composiciones de fexofenadina de la invención exhiben mejorada biodisponibilidad según se expresa como Cmax, la cantidad mínima de ingrediente activo encontrada en el plasma, o como AUC, el área debajo de la curva de la concentración en el plasma contra el tiempo.
EC2006006327A 2003-07-31 2006-01-27 Composición de fexofenadina y proceso para prepararla ECSP066327A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/631,874 US20050065183A1 (en) 2003-07-31 2003-07-31 Fexofenadine composition and process for preparing

Publications (1)

Publication Number Publication Date
ECSP066327A true ECSP066327A (es) 2006-07-28

Family

ID=34135544

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006327A ECSP066327A (es) 2003-07-31 2006-01-27 Composición de fexofenadina y proceso para prepararla

Country Status (12)

Country Link
US (1) US20050065183A1 (es)
EP (1) EP1651218A1 (es)
JP (1) JP2007500682A (es)
AR (1) AR045193A1 (es)
AU (1) AU2004262914A1 (es)
BR (1) BRPI0413186A (es)
CR (1) CR8220A (es)
EC (1) ECSP066327A (es)
NO (1) NO20060991L (es)
RU (1) RU2006105720A (es)
WO (1) WO2005013987A1 (es)
ZA (1) ZA200600519B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03009259A (es) * 2001-04-09 2004-06-03 Teva Pharma Polimorfos de clorhidrato de fexofenadina.
NZ548212A (en) 2003-12-29 2010-07-30 Sepracor Inc Pyrrole and pyrazole DAAO inhibitors
WO2005102999A2 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
EP1685106A2 (en) * 2004-09-28 2006-08-02 Teva Pharmaceutical Industries, Inc. Fexofendadine crystal form and processes for its preparation thereof
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
EP1808163A1 (en) * 2005-12-22 2007-07-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
WO2007073389A1 (en) * 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
CA2652300A1 (en) * 2006-05-15 2007-11-22 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
RU2453315C2 (ru) * 2010-08-17 2012-06-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения аллергических заболеваний
EP2618827B1 (en) * 2010-09-21 2021-06-02 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
JP2013119540A (ja) * 2011-12-08 2013-06-17 Nipro Corp 固形医薬組成物およびその製造法
JP6040218B2 (ja) * 2012-02-23 2016-12-07 フロイント産業株式会社 口腔内崩壊錠用直打賦形剤及びその製造方法、並びに口腔内崩壊錠
JP6184727B2 (ja) * 2013-04-15 2017-08-23 ロート製薬株式会社 医薬組成物
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
CN106137989A (zh) * 2016-07-20 2016-11-23 南通雅本化学有限公司 一种基于盐酸非索非那定的药物组合物
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
JP6410895B2 (ja) * 2017-07-26 2018-10-24 ロート製薬株式会社 医薬組成物
JP2019011350A (ja) * 2018-09-25 2019-01-24 ロート製薬株式会社 医薬組成物
JP2024500567A (ja) * 2020-12-11 2024-01-09 アヴァカ ファーマ プライベート リミテッド フェキソフェナジンを含む組成物
GB2629127A (en) 2022-08-31 2024-10-23 Novumgen Ltd An orodispersible tablet of fexofenadine and its process of preparation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
JPS52151717A (en) * 1976-06-09 1977-12-16 Shionogi & Co Ltd Sugar coating on solid preparations
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
JPS6183123A (ja) * 1984-09-28 1986-04-26 Taisho Pharmaceut Co Ltd 抗喘息剤
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
NZ251834A (en) * 1992-05-11 1997-07-27 Merrell Dow Pharma Use of acid derivatives of terfenadine as antihistamines
DK1026147T3 (da) * 1993-06-24 2004-03-22 Albany Molecular Res Inc Forbindelser, der er anvendelige som mellemprodukter i fremstillingen af piperidinderivater
DE69624559T2 (de) * 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JPH09315971A (ja) * 1996-05-28 1997-12-09 Daito Kk テルフェナジン含有錠剤製剤
PT1586314E (pt) * 1996-11-15 2011-07-01 Ajinomoto Kk Composição de comprimidos de nateglinida
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
WO2000038650A1 (en) * 1998-12-23 2000-07-06 Alza Corporation Gastric retention dosage form having multiple layers
EP1054019A1 (en) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6375982B1 (en) * 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine

Also Published As

Publication number Publication date
ZA200600519B (en) 2007-01-31
EP1651218A1 (en) 2006-05-03
RU2006105720A (ru) 2007-09-10
NO20060991L (no) 2006-04-28
AU2004262914A1 (en) 2005-02-17
JP2007500682A (ja) 2007-01-18
US20050065183A1 (en) 2005-03-24
BRPI0413186A (pt) 2006-10-03
WO2005013987A1 (en) 2005-02-17
CR8220A (es) 2006-07-27
AR045193A1 (es) 2005-10-19

Similar Documents

Publication Publication Date Title
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
BRPI0413186A (pt) composição de fexofenadina e processo para preparação da mesma
NO20074619L (no) Spiro-oksindolforbindelser og deres anvendelse som medikamenter
NO20081038L (no) Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
WO2009036341A3 (en) Compositions and methods relating to hiv protease inhibition
JP2025507472A5 (es)
SE0102440D0 (sv) New compound
ECSP044979A (es) Uso de bibn4096 en combinación con otros fármacos antimigrañosos para el tratamiento de migraña
SE0401655D0 (sv) New compounds
MX2022000411A (es) Composicion farmaceutica que comprende un compuesto de tetrahidropirazolopirimidinona.
NO20092764L (no) Isosorbid mononitrat derivater for behandling av okular hypertensjon
BR0203517A (pt) Composição farmacêutica estéril aquosa, e, método para preparar uma composição farmacêutica estéril aquosa
EA200600866A1 (ru) Применение галоидного производного гидроксимовой кислоты для лечения нейродегенеративных заболеваний
BRPI0409881A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
TW200800984A (en) New compounds
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa
ZA202404160B (en) Oral solution containing lisdexamfetamine and process for the preparation thereof
AR043793A1 (es) Uso del hidrocloruro de la base del principio activo 1-[n2-[3,5-didromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptano para el tratamiento de la migrana
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
AR067038A1 (es) Composicion farmaceutica que comprende la combinacion de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
AR032479A1 (es) Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina
EA200701503A2 (ru) Твердая пероральная лекарственная форма триметазидина дигидрохлорида с пролонгированным высвобождением, способ ее получения и способ лечения